HPV-FASTER: broadening the scope for prevention of HPV-related cancer

Bosch, F. Xavier; Robles, Claudia; Díaz, Mireia; Arbyn, Marc; Baussano, Iacopo; Clavel, Christine; Ronco, Guglielmo; Dillner, Joakim; Lehtinen, Matti; Petry, Karl‐Ulrich; Poljak, Mario; Kjær, Susanne K.; Meijer, Chris J.L.M.; Garland, Suzanne M.; Salmerón, Jorge; Castellsagué, Xavier; Bruni, Laia; Sanjosé, Sílvia de; Cuzick, Jack

doi:10.1038/nrclinonc.2015.146

Cited by 172 publications

(150 citation statements)

References 122 publications

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…20 Bosch et al, 2016), combined with the increasing role of HPV testing in cervical screening, means that the screening landscape will undergo considerable change in the coming years.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Psycho-social influences upon older women's decision to attend cervical screening: A review of current evidence

Hope

Moss

Redman

et al. 2017

Preventive Medicine

View full text Add to dashboard Cite

ACCEPTED MANUSCRIPT ABSTRACTCervical cancer is the fourth most common cancer in women worldwide (WHO, 2016). In many developed countries the incidence of cervical cancer has been significantly reduced by the introduction of organised screening programmes however, in the UK, a fall in screening coverage is becoming a cause for concern. Much research attention has been afforded to younger women but age stratified mortality and incidence data suggest that older women's screening attendance is also worthy of study. This paper provides a review of current evidence concerning the psycho-social influences that older women experience when Highlights There has been a lack of research on older women and cervical screening  This is at odds with age stratified incidence and mortality data  Embarrassment and logistical issues may deter older women from cervical screening  Psychological, emotional and physical age related changes can also play a role  Further research to enable informed decision-making among older women is required ACCEPTED MANUSCRIPT

show abstract

“…20 Bosch et al, 2016), combined with the increasing role of HPV testing in cervical screening, means that the screening landscape will undergo considerable change in the coming years.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Psycho-social influences upon older women's decision to attend cervical screening: A review of current evidence

Hope

Moss

Redman

et al. 2017

Preventive Medicine

View full text Add to dashboard Cite

show abstract

“…15 In accordance with this proposal, HPV vaccination of women in a broad age range can offer protection to women who are not currently infected, but also can protect against subsequent re-infection. 15 As a result, a combined strategy of HPV vaccination and screening may reduce the lifetime number of screens used by the current hrHPV-based screening programs. If a screening and vaccination strategy is widely adopted, we expect promising results.…”

Section: 2mentioning

confidence: 93%

HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico

Salmerón¹,

Torres‐Ibarra²,

Bosch³

et al. 2016

Salud Publica Mex

Self Cite

View full text Add to dashboard Cite

Objective. To outline the design of a clinical trial to evaluate the impact of HPV vaccination as part of a hrHPV-based primary screening program to extend screening intervals. Materials and methods. A total of 18,000 women aged 25-45 years, attending the regular cervical cancer-screening program in primary health care services in Tlalpan, Mexico City, will be invited to the study. Eligible participants will be assigned to one of three comparison groups: 1) HPV16/18 vaccine and hrHPV-based screening; 2) HPV6/11/16/18 vaccine and hrHPV-based screening; 3) Control group who will receive only hrHPV-based screening. Strict surveillance of hrHPV persistent infection and occurrence of precancerous lesions will be conducted to estimate safety profiles at different screening intervals; participants will undergo diagnosis confirmation and treatment as necessary. Conclusion. The FASTER-Tlalpan Study will provide insights into new approaches of cervical cancer prevention programs. It will offer valuable information on potential benefits of combin- ResumenObjetivo. Describir los métodos de un ensayo clínico que permita evaluar el impacto de la incorporación de la vacunación contra VPH en el programa de detección oportuna de cáncer cervical con el fin de ampliar los intervalos de tamizaje. Material y métodos. Un total de 18 000 mujeres entre 25 y 45 años, usuarias del programa de detección oportuna de cáncer cervical de la Ciudad de México en Tlalpan, serán invitadas a participar en el estudio. Las mujeres elegibles serán aleatorizadas a uno de tres grupos de comparación: 1) Vacunación contra VPH16/18 y tamizaje con VPHar; 2) Vacunación contra VPH6/11/16/18 y tamizadas con VPHar; 3) Grupo control que será sólo tamizado con VPHar. Se llevará a cabo una estrecha vigilancia de la infección persistente de VPHar y de la ocurrencia de lesiones precancerosas, con el fin de estimar el perfil de seguridad de intervalos de tamizaje de distinta duración. Todas las participantes contarán con procedimientos de confirmación diagnóstica y tratamiento en caso necesario. Conclusión. El estudio FASTER-Tlalpan http://dx.doi.org/10.21149/spm.v58i2.7790

show abstract

“…Synergy between primary and secondary prevention is being explored, for instance by extending routine vaccination programs to women of up to 30 years of age (and to the 45-year in some settings), in combination with at least one HPV-screening test at age 30 years or older [58]. Preliminary studies are being undertaken in high income countries, but might be an attractive approach for middle-income countries in Central and Eastern Europe, Latin America, Asia, and Africa, in the presence of political will, adequate planning, and an affordable price of the vaccines.…”

Section: Broadened Scope For Prevention Of Hpv-related Cancersmentioning

confidence: 99%

Overcoming barriers in HPV vaccination and screening programs

Vorsters

Arbyn

Baay³

et al. 2017

Papillomavirus Research

Self Cite

View full text Add to dashboard Cite

A B S T R A C TThe Human Papillomavirus Prevention and Control Board brought together experts to discuss optimizing HPV vaccination and screening programs.Board members reviewed the safety profile of licensed HPV vaccines based on clinical and post-marketing data, reaching a consensus that current safety data is reassuring.Successful vaccination programs used well-coordinated communication campaigns, integrating (social) media to spread awareness. Communication of evidence supporting vaccine effectiveness had beneficial effects on the perception of the vaccine. However, anti-vaccination campaigns have threatened existing programs in many countries.Measurement and monitoring of HPV vaccine confidence over time could help understand the nature and scale of waning confidence, define issues and intervene appropriately using context-specific evidence-based strategies. Finally, a broad group of stakeholders, such as teachers, health care providers and the media should also be provided with accurate information and training to help support prevention efforts through enhanced understanding of the risks and benefits of vaccination.Similarly, while cervical cancer screening through population-based programs is highly effective, barriers to screening exist: awareness in countries with population-based screening programs, access for vulnerable populations, and access and affordability in low-and middle-income countries. Integration of primary and secondary prevention has the potential to accelerate the decrease in cervical cancer incidence. IntroductionThe HPV Prevention and Control Board was created in December 2015 [1] with the aim to share relevant information on HPV with a broad array of stakeholders, and to implement preventive strategies to reduce the HPV-related disease burden. Here we report the discussion that took place during the first official meeting, held on June 27 and 28, 2016, in Antwerp, Belgium.1The objectives of the meeting were (a) to summarize the available adverse event profile and any reported safety concerns following HPV vaccination, (b) to summarize cultural, perceptual, infrastructural and financial barriers to the implementation of vaccination, (c) to identify factors that influence adherence to cervical screening programs, (d) to propose strategies to build public confidence in HPV prevention programs and address any vaccination and screening hesitancy, and (e) to discuss new approaches to improve HPV prevention and cervical cancer control. Vaccine safety profileThe safety of new products is critical for licensure and successful implementation/uptake. Critical review of clinical trial data is the first step in this process. However, as clinical trials generally involve limited numbers, and participants may have health conditions different from those in the general population, post-marketing surveillance is essential.While licensure has varied according to country, HPV vaccines have been available since 2006 beginning with the quadrivalent (4vHPV, Gardasil, Merck), followed by the bivalent (2vHP...

show abstract

HPV-FASTER: broadening the scope for prevention of HPV-related cancer

Cited by 172 publications

References 122 publications

Psycho-social influences upon older women's decision to attend cervical screening: A review of current evidence

Psycho-social influences upon older women's decision to attend cervical screening: A review of current evidence

HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico

Overcoming barriers in HPV vaccination and screening programs

Contact Info

Product

Resources

About